

# **Excess Insulin as a Driver for Insulin Resistance, NAFLD and Type 2 Diabetes: Pathophysiological Mechanisms and Therapeutic Opportunities**

A Thesis  
Submitted  
by

**Abhinav Choubey  
(Roll No: D16069)**

For

The award of the degree of

**Doctor of Philosophy**

*Under the supervision of*

**Dr. Prosenjit Mondal**

**(Associate Professor)**



**School of Basic Sciences**

**Indian Institute of Technology Mandi**

**Mandi, Himachal Pradesh, India-175005**

## Declaration by the Research Scholar

---

I hereby declare that the entire work embodied in the Thesis “**Excess Insulin as a Driver for Insulin Resistance, NAFLD and Type 2 Diabetes: Pathophysiological Mechanisms and Therapeutic Opportunities**” is the result of investigations carried out by me in the School of Basic Sciences, Indian Institute of Technology Mandi, under the supervision of **Dr. Prosenjit Mondal**, and that it has not been submitted elsewhere for any degree or diploma. In keeping with the general practice, due acknowledgements have been made wherever the work described is based on the finding of other investigators.

IIT Mandi (H.P.)

Date:

Signature: 

Name: **Abhinav Choubey**

## Declaration by the Research Advisor

---

I hereby certify that the entire work in this thesis has been carried out by **Abhinav Choubey (Roll No D16069)**, under my supervision in the **School of Basic Sciences**, Indian Institute of Technology Mandi and that no part of it has been submitted elsewhere for any Degree or Diploma.

**Signature:**

A handwritten signature in black ink that reads "Prosenjit Mondal". The signature is written in a cursive style with a horizontal line above and below the name.

**Name of the Guide:** Dr. Prosenjit Mondal

**Date :** 16/06/2021

*Consciously, this work is  
dedicated to “Lord Krishna”  
Animal Sacrificed, Teachers,  
Family, Beloved, Friends,  
Indian Farmers, and Soldiers.*

## Acknowledgement

Foremost, I owe my everything to the almighty “**LORD KRISHNA**” for his blessings in the accomplishment of the work.

I take this opportunity to express gratitude and appreciation to my supervisor **Dr. Prosenjit Mondal** (Associate Professor, School of Basic Sciences, BIOX centre, Indian Institute of Technology Mandi, Himachal Pradesh, India) for his excellent supervision, guidance, motivations towards me and my project and providing the best working culture.

Lots of appreciation to our collaborators, **Prof. Bikash Medhi, Dr. Ajay Prakash, Prof. Anil Bhansali** for the clinical facility in PGIMER-Chandigarh, **Dr. Debabrata Ghosh**, for the animal facility in IITR Lucknow, **Prof. Ullas S Kolthur** from TIFR-Mumbai for providing genetic mice model and **Dr. Sunil Kumar** from ICAR-Delhi for *in-silico* studies.

I am thankful to all DC members **Dr. Shyam Kumar Maskapalli, Dr. Amit Prasad, Dr. Amit Jaiswal, Dr. Aditya Nigam**, for their valuable suggestions and assessment throughout my Ph.D. I take this opportunity to thanks the Director of IIT Mandi, Advanced Materials Research Centre, BIOX Centre, IIT Mandi, and the DST-Inspire team.

I feel incredibly motivated to have the support of PM Lab members Khyati, Vineeth, Surbhi, Priya, Nikita Shilpa, Deepak. Thanks to my friends Aditya, Shaivya, Kundlik, Prem, Shounak, Ankita, Taniya, Riman for scientific and mental support. I would like to thank the non-technical staff, night watchmen, who accompanied me during my project work on days' nights. A deep sense of respect to ISKCON and its members for allowing me to get familiar with the most transcendental and confidential knowledge which also helped in this work.

Last, but first in my mind I thank my Parents, Family, Shilpi, and Gambhira for being my endless source of inspiration and confidence.

**Abhinav Choubey**

## Preface

Type 2 diabetes (T2DM) and Non-alcoholic fatty liver (NAFLD) represents the most alarming dual epidemic concern of the 21st century. The prevalence/complexity of this looming epidemic is increasing severely and WHO predicts the incidence to double by 2030. T2DM is characterized by elevated blood glucose (hyperglycaemia) which is a result of peripheral insulin resistance where the body fails to use insulin and compensatory hyperinsulinemia where the pancreas is forced to secrete more insulin (in settings of insulin resistance). Hyperinsulinemia, a state of elevated circulatory insulin level is considered both a cause and consequence of insulin resistance, however the mechanism of how it causes insulin resistance is unknown. Several lines of evidence have shown that high insulin predisposes individuals toward metabolic illness. The two main causes of hyperinsulinemia are  $\beta$ -cell hypersecretion with or without an insulin-resistant state and decreased clearance of insulin from systemic circulation. Existing pieces of literature have also shown that T2DM, obesity, and its associated fatty liver can be reversed with a specific, partial reduction of insulin production. However, the lack of knowledge on how an excess of insulin drives insulin resistance and the unavailability of a proper pharmacological correction of circulatory high insulin put an immense area to look into. Thus, taking the need of current limitation, we deciphered the molecular mechanism on how high insulin induces systemic insulin resistance, NAFLD and also revealed that a low dose of naltrexone has a significant potential to protect against such states. Altogether these data provide evidence for the causal role of hyperinsulinemia in the progression of insulin resistance and fatty liver pathology and a low dose of naltrexone improves hyperinsulinemia mediated metabolic health

<u>DECLARATION BY THE RESEARCH SCHOLAR</u>	<u>I</u>
<u>DECLARATION BY THE RESEARCH ADVISOR</u>	<u>II</u>
<u>ACKNOWLEDGEMENT</u>	<u>IV</u>
<u>PREFACE</u>	<u>V</u>
<u>ABBREVIATION</u>	<u>X</u>
<u>LIST OF FIGURES</u>	<u>XVIII</u>
<u>LIST OF TABLES</u>	<u>XX</u>
<u>CHAPTER 1</u>	<u>1</u>
<u>INTRODUCTION AND REVIEW LITERATURE</u>	<u>2</u>
<b>1.1 INTRODUCTION</b>	<b>2</b>
<b>1.2 DISEASE PROJECTION AND MAJOR RISK FACTORS</b>	<b>2</b>
<b>1.3 INSULIN AND GLYCAEMIC CONTROL</b>	<b>3</b>
<b>1.4 INSULIN RESISTANCE</b>	<b>5</b>
<b>1.5. HYPERINSULINEMIA</b>	<b>6</b>
1.5.A. INSULIN HYPERSECRETION-	6
1.5.B. IMPAIRED INSULIN CLEARANCE-	7
<b>1.6 MOLECULAR INTERCONNECTION BETWEEN INFLAMMATION, INSULIN RESISTANCE, T2DM, AND NAFLD</b>	<b>7</b>
1.6.A. INCREASED DE-NOVO LIPOGENESIS	8
1.6.B IMPAIRED AUTOPHAGY	9
1.6.C. LOW CHRONIC GRADE INFLAMMATION	10
<b>1.7. MAJOR CHALLENGES ASSOCIATED WITH T2DM AND NAFLD</b>	<b>12</b>
<b>1.8 HYPERINSULINEMIA A PROBABLE EVENT TO TARGET METABOLIC DISORDER AT EARLY STAGES</b>	<b>13</b>
<b>1.9 KEY HYPOTHESIS</b>	<b>15</b>
<u>OBJECTIVES OF THE THESIS</u>	<u>18</u>
<u>CHAPTER 2</u>	<u>21</u>
<u>LOW-DOSE NALTREXONE RESCUES INFLAMMATION AND INSULIN RESISTANCE ASSOCIATED WITH HYPERINSULINEMIA</u>	<u>22</u>

<u>SUMMARY</u>	<u>22</u>
----------------	-----------

<b>2.1. INTRODUCTION</b>	<b>23</b>
<b>2.2 EXPERIMENTAL PROCEDURES</b>	<b>25</b>
2.2.1 DRUGS AND CHEMICALS	25
2.2.2 CELL LINES AND CULTURE TREATMENT	25
2.2.3 CELL VIABILITY	26
2.2.4 RNA ISOLATION AND GENE EXPRESSION PROFILE	26
2.2.5 WESTERN BLOT ANALYSIS	27
2.2.6 NF- $\kappa$ B REPORTER ASSAY	29
2.2.7 IMMUNOCYTOCHEMISTRY	29
2.2.8 SIRT1 DEGRADATION ASSAY	30
2.2.9 siRNA TRANSFECTION	30
2.2.10 ANIMALS AND TREATMENTS	30
2.2.11 METABOLIC PARAMETERS ANALYSIS	31
2.2.12 ATMs ISOLATION AND ANALYSIS	32
2.2.13 SERUM ELISA	32
2.2.14 DOCKING SIMULATION	33
2.2.15 MST MEASUREMENTS	33
2.2.16 STATISTICAL ANALYSIS	34
<b>2.3 RESULTS</b>	<b>34</b>
2.3.1 LDN TREATMENT IMPROVES GLUCOSE TOLERANCE AND INSULIN SENSITIVITY IN HFD-INDUCED HYPERINSULINEMIC MICE	34
2.3.2 LDN SUPPRESSES HYPERINSULINEMIA-INDUCED PRO-INFLAMMATORY CYTOKINE RELEASE	36
2.3.3 LDN SUPPRESSES HYPERINSULINEMIA-INDUCED CYTOSOL-NUCLEUS TRANSLOCATION OF NF- $\kappa$ B	40
2.3.4 LDN TREATMENT PROTECTS SIRT1 FROM HYPERINSULINEMIA-INDUCED DOWNREGULATION IN THE HFD MICE MODEL	42
2.3.5 SIRT1 IS CRITICAL FOR LDN-MEDIATED ANTI-INFLAMMATORY EFFECTS	44
2.3.6 LDN BINDS TO SIRT1 AND INCREASES ITS DEACETYLASE ACTIVITY <i>IN-VITRO</i>	47
<b>2.4 DISCUSSION</b>	<b>49</b>

<u>CHAPTER 3</u>	<u>52</u>
------------------	-----------

<u>HMGB1 RELEASE AND SOLUBLE CD14 REGULATES HYPERINSULINEMIA MEDIATED INSULIN RESISTANCE: LOW DOSE NALTREXONE MAINTAIN NUCLEAR HMGB1 IN HYPERINSULINEMIC CONDITION</u>	<u>53</u>
--	-----------

<u>SUMMARY</u>	<u>53</u>
----------------	-----------

<b>3.1 INTRODUCTION</b>	<b>55</b>
<b>3.2. METHODS</b>	<b>57</b>



3.2.1. CELL LINES AND CULTURE TREATMENT	57
3.2.2. RNA ISOLATION AND GENE EXPRESSION PROFILE	57
3.2.3. WESTERN BLOT ANALYSIS	58
3.2.4. siRNA TRANSFECTION	60
3.2.5. IMMUNOCYTOCHEMISTRY	60
3.2.6. SITE-DIRECTED MUTAGENESIS OF HMGB1-	60
3.2.7. MST MEASUREMENTS-	61
3.2.8. THE LIGAND BLOT ASSAY FOR INSULIN-CD14 BINDING ANALYSIS	61
3.2.9. PROTEIN-PROTEIN INTERACTION AND MOLECULAR DYNAMICS SIMULATION	62
3.2.10. MICE	62
3.2.11. GENETICALLY DEFINED SIRT1 MICE MODELS	63
3.2.12. TISSUE LYSATE PREPARATION-	63
3.2.13. METABOLIC PARAMETERS ANALYSIS-	64
3.2.14. SUBCELLULAR FRACTIONATION-	64
3.2.15. CLINICAL EXPERIMENTATION AND SUBJECT DETAILS-	64
3.2.16. STATISTICAL ANALYSIS-	64
<b>3.3. RESULTS:</b>	<b>65</b>
3.3.1. HYPERINSULINEMIA FAILS TO INDUCE PRO-INFLAMMATION IN TLR4 ABSENCE.	65
3.3.2. INSULIN INTERACTS WITH CD14 AND ACTS AS A LIGAND FOR CD14 RECEPTORS:	67
3.3.3. IDENTIFICATION OF THE FACTOR LINKING HYPERINSULINEMIA AND TLR4 ACTIVATION INDIRECTLY: SERUM HMGB1 WAS DIRECTLY PROPORTIONAL TO INCREASE IN SERUM INSULIN.	71
3.3.4. LDN RESCUES FROM HYPERINSULINEMIA INDUCED HMGB1 RELEASE.	73
3.3.5. HYPERINSULINEMIC SERUM BLUNTS INSULIN RESISTANCE IN HEPATOCYTE AND LDN PREVENTS FROM SUCH EVENT.	73
3.3.6. NEUTRALIZING HMGB1 PREVENTS DIABETIC SERUM TO BLUNT INSULIN SIGNALING IN HEPATOCYTES:	74
3.3.7. HYPERINSULINEMIA PROMOTE HYPER ACETYLATION AND NUCLEO-CYTOSOLIC SHUTTLING OF HMGB1 AND LDN PREVENTED FROM SUCH CONSEQUENCES.	76
3.3.8. HYPERINSULINEMIA FAILS TO INDUCE HMGB1 NUCLEO-CYTOSOLIC SHUTTLING AND EXTRACELLULAR RELEASE IN HMGB1 ACETYLATION-DEFICIENCY STATE.	78
3.3.9. MECHANISTIC CONNECTION BETWEEN SIRT1, BASAL HYPERINSULINEMIA AND HMGB1 TRANSLOCATION IN GENETICALLY DEFINE MOUSE MODELS.	80
<b>3.4.DISCUSSION</b>	<b>83</b>
 <b>CHAPTER 4</b>	 <b>87</b>
 <u>DECODING THE MOLECULAR BASIS FOR THE FATTY LIVER PATHOGENIES MEDIATED BY HYPERINSULINEMIA AND EXPLORING THE RESCUING POTENTIAL OF LDN.</u>	 <u>88</u>
 <b>SUMMARY:</b>	 <b>88</b>
 <b>4.1. INTRODUCTION</b>	 <b>90</b>

<b>4.2. MATERIAL AND METHOD</b>	<b>92</b>
4.2.1. DRUGS AND CHEMICALS	92
4.2.2. CELL LINES AND CULTURE TREATMENT	92
4.2.3. WESTERN BLOT ANALYSIS	92
4.2.4. SURFACE SENSING OF TRANSLATION (SUNSET) ASSAY	93
4.2.5. AUTOPHAGIC FLUX ASSAY	94
4.2.6. BODIPY AND ACRIDINE ORANGE STAINING	94
4.2.7. IMMUNOCYTOCHEMISTRY	94
4.2.8. ANIMALS AND TREATMENTS	94
4.2.9. HISTOPATHOLOGICAL ANALYSIS	95
4.2.10. APOPTOSIS ASSAY	95
4.2.11. STATISTICAL ANALYSIS	95
<b>4.3. RESULT:</b>	<b>96</b>
4.3.1. HYPERINSULINEMIA INDUCES LIPID ACCUMULATION IN THE LIVER AND LDN TREATMENT RESCUES FROM DIET INDUCED FATTY LIVER.	96
4.3.2. HYPERINSULINEMIA COMPROMISE LYSOSOMAL ACTIVITY TO BRING HEPATIC AUTOPHAGY FLUX OBSTRUCTION, AND LDN REVERSE THE EVENT.	97
4.3.3. INCREASED ER STRESS CORRELATES WITH IMPAIRED HEPATIC AUTOPHAGY FLUX/ P62 ACCUMULATION AND LDN AMELIORATED THIS PATHOLOGICAL EVENT.	100
4.3.4. HYPERINSULINEMIA PROMOTES SREBP1C NUCLEAR LOCALIZATION AND LDN PREVENTS FROM SUCH EVENTS.	103
4.3.5. LDN MEDIATED ER STRESS IMPROVEMENT IN HEPATIC STEATOSIS IS SIRT1 DEPENDENT.	104
4.3.6. LDN RESCUES APOPTOTIC CELL DEATH IN DIET-INDUCED HYPERINSULINEMIC MICE LIVER.	105
<b>4.4. DISCUSSION:</b>	<b>106</b>
<b>CHAPTER 5</b>	<b>109</b>
<hr/>	
<b>CONCLUSION AND FUTURE DIRECTION</b>	<b>109</b>
<hr/>	
<b>SIGNIFICANCE AND MAIN CONTRIBUTIONS OF THE THESIS</b>	<b>109</b>
<b>FUTURE DIRECTION.</b>	<b>112</b>
<b>REFERENCES</b>	<b>114</b>
<hr/>	